Search
Search
Close this search box.

Delta-8 ‘Already Extremely Accessible to Teens’ Despite Growing Efforts to Ban Substance

Delta-8-THC, a semi-synthetic cannabinoid typically derived from hemp, is ‘already extremely accessible to teens’ despite growing efforts to crack down on the substance, according to a new study.

According to an analysis of data from the National Institute of Health-funded ‘2023 Monitoring the Future Survey’, 11% of 12th graders (17-18 years old) reported using delta-8 in the past year.

In what is reportedly the first such study into the drug’s use among US teens, around 91% of those who reported delta-8 use also reported cannabis use in the past year.

Approximately 30% of 12th graders reported cannabis use in 2023, according to the same study.

Unsurprisingly, use of delta-8, which is available for under 18’s to purchase online or in convenience stores across much of the US, is more common in states where there is no cannabis legalisation or delta-8 regulation.

“11% is a lot of people – that’s at least one or two students in every average-sized high school class who may be using delta-8. We don’t know enough about these drugs, but we see that they are already extremely accessible to teens,” said Nora Volkow, M.D., NIDA director.

Richard A. Miech, Ph.D., team lead of the Monitoring the Future study at the University of Michigan and co-author of the study, added: “The national trends documented by the Monitoring the Future survey provide critical information for research and policy to keep pace with new developments in the market for cannabis products, which has seen considerable change in recent years.”

Earlier this month, Florida approved a bill to regulate hemp-derived products and ban delta-8 outright, taking the number of states to ban the substance to 17, alongside seven more that have restricted it severely.

⏰ Pre-order discount ends Jan 15
-- Days
-- Hours
-- Mins
Data packs delivered January 2026
🔬 New Report Due January 2026

Global Medical Cannabis Market Review 2026

A comprehensive analysis of the international medical cannabis supply chain — examining country-specific data on exports, imports, market size, domestic production, and distribution landscapes. Understand the driving forces behind global supply dynamics, the impact of telemedicine on patient access, and regulatory changes shaping the market.

What's covered

  • 📊 Global supply chain overview — understand export/import dynamics and domestic production capabilities
  • 🌍 8 export country snapshots — Canada, Portugal, Denmark, North Macedonia, Spain, Australia, Czech Republic, South Africa
  • 👥 6 patient market snapshots — Australia, Germany, UK, Poland, Brazil, France
  • 🔮 Key themes — Canada's global impact, telemedicine growth, new market openings, quota changes
Export Markets
🇨🇦 Canada 🇵🇹 Portugal 🇩🇰 Denmark 🇲🇰 N. Macedonia 🇪🇸 Spain 🇦🇺 Australia 🇨🇿 Czechia 🇿🇦 South Africa
Patient Markets
🇦🇺 Australia 🇩🇪 Germany 🇬🇧 UK 🇵🇱 Poland 🇧🇷 Brazil 🇫🇷 France
100% free • No credit card required
As trusted by
DIAGEO KPMG Coca-Cola BARCLAYS BNP PARIBAS AB InBev NOVARTIS Johnson & Johnson PEPSICO AXA POLITICO Bloomberg amazon CNN Business
Part of our annual market review series GDPR compliant

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?